Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

2013 JIB Congress to Emphasize New Perspectives in Medical Biology

By BiotechDaily International staff writers
Posted on 15 Jul 2013
Print article
A new governance has been set up to organize the next Journées Internationales de Biologie (JIB; Paris, France), its 58th annual meeting of medical biologists, to be held November 13–15, 2013 at the CNIT Paris, La Défense. In order to place the congress as a key "laboratory agenda" professional event, JIB renews itself not only as a recurring gathering for the profession, but also as an opportunity to gain fresh, positive perspectives on one's daily practice in the laboratory.

In order to optimize attendee presence at the meeting, efficiency is emphasized in enabling participants in each area to gather, individually or collectively, in a productive manner. Medical biologists can find solutions in various missions (HR, quality, logistics, finance, etc.) and fields (hematology, virology, biochemistry, etc.) by their participation in the congress, the exhibition, and the JIB Awards. Discussions and exchanges between specialists take place on the "Paroles d’Experts.” The "Institutions Corner" brings together various authorities for the profession (regional associations, societies, orders, ministries, syndicates, or humanitarians). JIB is also committed to the new generation and has dedicated the "Recruitment Sphere" section with practical workshops to help facilitate access and integration of new biologists to the professional world.

The exhibition platform for launching innovations will present nearly 200 technological advances and solutions, of which 75% have a European and worldwide scope, and 78% are presented for the first time. Innovation is particularly visible at the "Innovation Gallery," and is further emphasized at the JIB Awards ceremony, provided for the second time after its success in 2012, now with six new categories: Procedures Improvement, Innovation Gallery, Quality and Accreditation, Emergency Biology and POC, Post Analytics Innovation, and the Jury’s Award.

The congress sessions mainly relate to the multidisciplinary aspect of medical biology, innovative laboratory equipment and technologies, and the role of biology in healthcare policies and organization. The inaugural session “Medical biology and screening policies” highlights biology in preventive and individualized medicine as the desired alternative to curative medicine. The session on “Nanotechnologies, first outcomes and perspectives in medical biology” presents an overview of the miniaturized technologies that are transforming diagnosis and follow-up methods. In parallel to the scientific sessions, the "Colloquium" offers working sessions to assist with various topics such as laboratory services, the medical biology laboratory in local health policies, and the evolution of the biomedical practice organization.

Related Links:

JIB - Journées Internationales de Biologie





Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A 3D nanofiber net formed by the supergelators to trap oil molecules (Photo courtesy of IBN at A*STAR / Institute of Bioengineering and Nanotechnology).

Effective Cleanup with Smart Material That Forms Oil-Trapping Net

Researchers have developed supergelators – an organic oil-scavenging material that rapidly forms a 3D net to trap oil molecules, gelatinizing into solidified masses that can be more easily removed from... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.